To subscribe to our optical e-newsletters and receive them via e-mail, click here.
How ‘real world’ clinical experience with anti-VEGF drugs in treating three FDA-approved indications differs from clinical trial results.
Advances in imaging technologies are changing both the way we think of the vitreous and how we treat patients.
Moving beyond the proof-of-concept stage, a greater emphasis on the functional outcomes of retinal implants is needed.
The power of genetically defined targets in the development of retinal therapies is beginning to bear fruit. Where it’s headed next.
We have learned much about the pathogenesis of PVR but have a lot of ground to cover to effectively treat this devastating disease.
Novel research is exploring protecting photoreceptors and the retinal pigment epithlium in multiple models of retinal disease.
The protocols for IVT injection continue to evolve as the procedure becomes one of the most-performed in U.S. medicine.
The use of stem cells to treat retinal disease has moved beyond the theoretical and proof-of-concept stages and into clinical trials.
Although many questions remain, anti-VEGF therapies for diabetic retinopathy treatment will dramatically alter the delivery of care.
Advances in optical coherence tomography reveal correlations between retinal anatomy and vision loss in several retinal diseases.
Copyright© 2000 - 2016 Jobson Medical Information LLC unless otherwise noted.
All rights reserved. Reproduction in whole or in part without permission is prohibited.